You can buy or sell Inovio and other stocks, options, and ETFs commission-free!
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP.
J. Joseph Kim
Plymouth Meeting, Pennsylvania
52 Week High
52 Week Low
Inovio to start global late-stage COVID-19 vaccine trial this summer
A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker in this illustration taken, October 30, 2020. REUTERS/Dado Ruvic/File Photo
Inovio's stock is up after it shares new data from Phase 2 clinical trial for its COVID-19 vaccine candidate
Shares of Inovio Pharmaceuticals Inc. INO, +5.22% gained 8.0% in premarket trading on Monday after the company said its experimental COVID-19 vaccine was safe a
-$0.18 per share
-$0.27 per share